Simultaneous overexpression of both HER2 and HER3 was found in several cancers (Naidu et al, 1998; Krahn et al, 2001), and increased drug resistance in many HER2-overexpressing cancers depends on increased levels of HER3 or EGFR (Chen et al, 2000). Here, ERBB2 is linked to cancer.